Drug intelligence / Profile preview

11-valent recombinant human papillomavirus vaccine

Development stage: Unknown
Lead developer: Sinopharm
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The **11-valent recombinant human papillomavirus vaccine** is an investigational prophylactic HPV vaccine produced in *Hansenula polymorpha*. It is intended to induce humoral and cellular immune responses against 11 HPV antigens, supporting prevention of HPV infection and HPV-associated cervical precancerous lesions, genital warts, and related anogenital disease. It has been evaluated in Chinese females using a three-dose intramuscular regimen at months 0, 2, and 6, with Phase III clinical evaluation registered in women aged 9–45 years.

Other names: 11-valent recombinant HPV vaccine11-valent recombinant human papilloma virus vaccine11-valent recombinant human papillomavirus vaccine11-valent recombinant human papillomavirus vaccine (Hansenula polymorpha)11-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha)

Targets

HPV L1 (Human papillomavirus L1 capsid protein)HPV16 E7 (Human papillomavirus 16 E7 protein)

Beyond the preview

Go deeper on 11-valent recombinant human papillomavirus vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 11-valent recombinant human papillomavirus vaccine.